These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9101815)

  • 1. [Use of recombinant erythropoietin in surgery--are the costs justified?].
    Wolff M; Fandrey J; Jelkmann W; Hirner A
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():143-5. PubMed ID: 9101815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Autologous blood donation versus homologous blood transfusion--an analysis of cost effectiveness].
    Dietrich GV
    Zentralbl Chir; 1996; 121(10):841-6. PubMed ID: 9019932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative use of recombinant human erythropoietin in pediatric orthopedics: a decision model for long-term outcomes.
    Vitale MG; Roye BD; Ruchelsman DE; Roye DP
    Spine J; 2007; 7(3):292-300. PubMed ID: 17482112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost analysis of autologous transfusion methods--a study of 5,017 patients].
    Singbartl G; Schleinzer W
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 Jun; 34(6):350-8. PubMed ID: 10429773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of the cost of autologous erythrocyte concentrates in a hospital].
    Gouëzec H; Tardivel R; Danic B; Ballay JL; Malledant Y
    Cah Anesthesiol; 1996; 44(5):451-4. PubMed ID: 9183429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased iron absorption during autologous blood donation supported by recombinant human erythropoietin therapy.
    Bovy C; Baudoux E; Salmon JP; Beguin Y
    Transfusion; 2006 Sep; 46(9):1616-23. PubMed ID: 16965592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An economic analysis of costs associated with development of a cell salvage program.
    Waters JR; Meier HH; Waters JH
    Anesth Analg; 2007 Apr; 104(4):869-75. PubMed ID: 17377098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of recombinant human erythropoietin in the management of anaemic cancer patients: focus on haematological malignancies.
    Osterbor A
    Med Oncol; 2000 Nov; 17 Suppl 1():S17-22. PubMed ID: 11188781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative recombinant human erythropoietin injection versus preoperative autologous blood donation in patients undergoing radical retropubic prostatectomy.
    Chun TY; Martin S; Lepor H
    Urology; 1997 Nov; 50(5):727-32. PubMed ID: 9372883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Erythrocytapheresis a few weeks before surgery: an alternative to erythropoietin treatment in programmed autologous transfusion].
    Bernière J; Gerota I
    Cah Anesthesiol; 1996; 44(4):303-8. PubMed ID: 9033827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A blood transfusion in Sweden--the societal cost].
    Glenngård AH; Persson U
    Lakartidningen; 2006 Sep 20-26; 103(38):2752-6. PubMed ID: 17058770
    [No Abstract]   [Full Text] [Related]  

  • 12. IL-6 and IL-8 response to erythropoietin therapy in radical hysterectomy.
    Hyllner M; Avall A; Bengtson JP; Bengtsson A
    Acta Anaesthesiol Scand; 2005 Jan; 49(1):47-51. PubMed ID: 15675981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimizing perioperative homologous blood exposure with recombinant human erythropoietin.
    Levine EA; Gould SA
    Surg Annu; 1993; 25 Pt 1():83-99. PubMed ID: 8416148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preoperative autologous blood donation].
    Osswald PM; Lorentz A
    Klin Anasthesiol Intensivther; 1993; 43():124-45. PubMed ID: 8421376
    [No Abstract]   [Full Text] [Related]  

  • 15. [Autologous blood donation with recombinant human erythropoietin prior to elective cardiac surgery in anemic patients].
    Kiyama H; Ohshima N; Imazeki T; Yamada T
    Kyobu Geka; 1998 Aug; 51(9):741-4. PubMed ID: 9742815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevention of neonatal anemia with recombinant human erythropoietin: a cost-benefit analysis].
    Schefels J; Merz U; Hörnchen H
    Z Geburtshilfe Neonatol; 1999 Dec; 203 Suppl 2():1-5. PubMed ID: 10612190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
    Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
    Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis of recombinant human erythropoietin in anemic cancer patients induced by chemotherapy in Thailand.
    Roungrong J; Teerawattananon Y; Chaikledkaew U
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S119-25. PubMed ID: 19255987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regarding the article "costs associated with blood transfusion in Sweden - the societal cost of autologous, allogeneic and perioperative RBC transfusion".
    Jidell E; Norda R; Berseus O; Swärd-Nilsson AM
    Transfus Med; 2006 Apr; 16(2):151-2; author reply 153. PubMed ID: 16623922
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of recombinant human erythropoietin therapy on blood coagulation and fibrinolysis system.
    Kobayashi T; Makuuchi H; Takahashi K; Furuse A; Shibata Y; Tsuno H; Kotsuka Y; Kubota H; Imanaka K; Tsukada T; Nakashima M
    Ann Thorac Cardiovasc Surg; 2001 Oct; 7(5):273-7. PubMed ID: 11743853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.